NSE LAURUSLABS · BSE 540222 · Biotechnology & Drugs · NIFTY 500

Laurus Labs Share Price

Market closed · updated 25 Sep, 4:42 PM IST

₹2,037.50 ▲ +₹0.81 · 0.04% NSE · as of 24 Sep 2026, 8:53 AM · BSE ₹2,035.70

Today's range

₹2,020.10Low₹2,054.55High

52-week range

₹822.85Low · 26 Sep 2025₹2,037.45High · 23 Sep 2026

Laurus Labs Overview

Where the price stands, how it has moved and how it sits against its averages.

Laurus Labs shares last traded at ₹2,037.50 on the NSE, up 0.04% on the day. That is 0.0% below the 52-week high of ₹2,037.45 and 147.6% above the 52-week low of ₹822.85. The stock trades at 74.91× earnings, above the sector average of 36.50. Its market value is ₹1,09,991 Cr.

Price returns

1 Day▲ +0.04%

5 Days▲ +6.74%

This month▲ +6.21%

3 Months▲ +39.87%

6 Months▲ +98.73%

This year▲ +83.57%

1 Year▲ +123.50%

Against the market: 1 Month ▲ +11.60% · 3 Months ▲ +43.91% · 6 Months ▲ +99.91% · This year ▲ +109.07% · 1 Year ▲ +145.23%

Shading grows with the size of the move. Prices refresh every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next update from Mon 28 Sep, 9:15 AM.

Moving averages — price is above 6 of 6

Today's price₹2,037.50
5-day average₹1,966.32 ▲ price 3.6% above
10-day average₹1,955.64 ▲ price 4.2% above
20-day average₹1,916.38 ▲ price 6.3% above
50-day average₹1,805.27 ▲ price 12.9% above
100-day average₹1,589.49 ▲ price 28.2% above
300-day average₹1,311.39 ▲ price 55.4% above

Averages above today's price sit higher on the ladder. Price above most of its averages is usually read as an upward trend.

Laurus Labs Financial Results

Revenue and net profit in ₹ crore, with the full statements underneath.

Revenue₹ crore

6,813

Net profit₹ crore · losses below zero

984

889

Year by year

Fiscal year	Revenue	Growth	Net profit	Net margin	EPS	Dividend
FY 2026	₹6,813 Cr	▲ +22.7%	₹889 Cr	13.0%	₹16.45	₹2.00
FY 2025	₹5,554 Cr	▲ +10.2%	₹358 Cr	6.5%	₹6.64	₹1.20
FY 2024	₹5,041 Cr	▼ −16.6%	₹161 Cr	3.2%	₹2.97	₹0.80
FY 2023	₹6,041 Cr	▲ +22.4%	₹790 Cr	13.1%	₹14.64	₹1.20
FY 2022	₹4,936 Cr	▲ +2.5%	₹828 Cr	16.8%	₹15.35	—
FY 2021	₹4,814 Cr	▲ +70.0%	₹984 Cr	20.4%	₹18.28	—
FY 2020	₹2,832 Cr	—	₹255 Cr	9.0%	₹4.79	—

Revenue₹ crore

2,026

Net profit₹ crore · losses below zero

368

Quarter by quarter

Quarter	Revenue	vs prev. qtr	Net profit	Net margin	EPS
Q1 FY27	₹2,026 Cr	▲ +11.9%	₹368 Cr	18.1%	₹6.80
Q4 FY26	₹1,812 Cr	▲ +1.9%	₹279 Cr	15.4%	₹5.17
Q3 FY26	₹1,778 Cr	▲ +7.5%	₹252 Cr	14.2%	₹4.65
Q2 FY26	₹1,653 Cr	▲ +5.3%	₹195 Cr	11.8%	₹3.61
Q1 FY26	₹1,570 Cr	▼ −8.8%	₹163 Cr	10.4%	₹3.02
Q4 FY25	₹1,720 Cr	▲ +21.6%	₹234 Cr	13.6%	₹4.33
Q3 FY25	₹1,415 Cr	▲ +15.6%	₹92 Cr	6.5%	₹1.71
Q2 FY25	₹1,224 Cr	—	₹20 Cr	1.6%	₹0.37

Balance sheet — FY26

Owes (liabilities)Shareholders' equity

50%

Total assets₹10,511 Cr
Total liabilities₹5,211 Cr
Shareholders' equity₹5,300 Cr
Total debt₹2,518 Cr
Cash & investments₹113 Cr
Current ratio1.33×
Revenue growth, 5 yr7.19% a year
EPS growth, 5 yr−2.09% a year
Operating margin (TTM)21.28%
Net margin (TTM)15.00%

Cash flow — FY26

Operating activities

▲ ₹1,624 Cr

Investing activities

▼ −₹1,089 Cr

Financing activities

▼ −₹525 Cr

Free cash flow

▲ ₹554 Cr

Net change in cash

▲ ₹13 Cr

Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.

Full financial statements, FY20–FY26

₹ crore	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Total revenue	2,831.72	4,813.51	4,935.57	6,040.55	5,040.83	5,553.96	6,812.90
Cost of revenue	1,580.80	2,355.12	2,452.79	3,164.81	2,837.24	2,862.81	3,134.78
Gross profit	1,250.92	2,458.39	2,482.78	2,875.74	2,203.59	2,691.15	3,678.12
Operating expenses	2,448.80	3,467.05	3,761.65	4,746.91	4,645.98	4,928.77	5,507.28
Operating income	382.92	1,346.46	1,173.92	1,293.64	394.85	625.19	1,305.62
Depreciation	187.32	205.07	251.49	324.08	384.58	430.09	480.05
Profit before tax	293.61	1,301.11	1,083.85	1,108.94	236.36	484.29	1,181.88
Tax	38.34	317.29	251.42	312.30	68.15	129.88	292.03
Net profit	255.27	983.58	827.52	790.11	160.55	358.32	888.79
EPS (₹)	4.79	18.28	15.35	14.64	2.97	6.64	16.45
Dividend per share (₹)	—	—	—	1.20	0.80	1.20	2.00

₹ crore	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Total assets	3,750.32	5,750.69	6,968.04	7,660.40	8,387.03	9,335.57	10,511.19
Current assets	1,812.05	3,074.86	3,344.61	3,461.68	3,834.97	4,332.32	4,829.21
Cash & short-term investments	1.69	48.46	75.35	45.67	138.94	99.54	112.66
Inventory	905.22	1,575.45	1,760.30	1,684.81	1,845.41	1,936.54	2,342.16
Property, plant & equipment	1,774.02	2,277.17	3,208.56	3,700.17	4,047.53	4,315.96	4,879.22
Total liabilities	1,980.54	3,153.14	3,616.85	3,622.87	4,276.08	4,863.01	5,211.13
Current liabilities	1,692.37	2,457.15	2,681.01	2,432.26	3,112.28	3,539.72	3,635.43
Total debt	1,079.43	1,481.69	1,776.66	2,015.09	2,577.40	2,763.73	2,518.48
Total equity	1,769.78	2,597.55	3,351.19	4,037.53	4,110.95	4,472.56	5,300.06

₹ crore	FY20	FY21	FY22	FY23	FY24	FY25	FY26
From operations	347.41	733.00	911.10	993.90	665.69	601.65	1,623.50
From investing	−221.12	−940.99	−914.34	−996.06	−822.42	−681.72	−1,088.66
From financing	−127.66	254.70	30.26	−26.64	249.83	39.28	−524.72
Capital expenditure	−222.19	−688.77	−876.84	−990.16	−678.31	−641.00	−1,069.95
Dividends paid	−32.00	−75.04	−85.86	−107.47	−86.18	−43.13	−86.33
Net change in cash	−1.28	46.77	26.89	−29.68	93.27	−39.40	13.12

What Analysts Say

12 analysts

Recommendations from 12 analysts who cover Laurus Labs.

Hold average rating 2.83 on a 1–5 scale

Strong buyBuyHoldSellStrong sell

▲ 5 bullish (41.7%) · 3 hold (25.0%) · ▼ 4 bearish (33.3%)

Votes

Strong Buy

2 (17%)

Buy

3 (25%)

Hold

3 (25%)

Sell

3 (25%)

Strong Sell

1 (8%)

How the votes changed

Rating	3M ago	2M ago	1M ago	1W ago	Now	3-month change
Strong Buy	2	2	2	2	2	—
Buy	3	3	3	3	3	—
Hold	3	3	3	3	3	—
Sell	3	3	3	3	3	—
Strong Sell	2	2	2	1	1	▼ −1

Analyst ratings are opinions, not a guarantee of returns.

Laurus Labs vs Peers

Side by side with other biotechnology & drugs companies. The small bars compare each column.

Company	Price	Change	Market cap	P/E	P/B	ROE (5 yr)	Net margin	Div. yield	Rating
Laurus Labs	₹2,037.50	▲ +0.04%	₹1,09,991 Cr	74.91	20.72	15.19%	15.00%	0.10%	This stock
Sun Pharmaceutical Industries	₹1,852.00	▼ −0.70%	₹4,44,346 Cr	38.40	5.55	14.22%	19.12%	0.83%	Moderately Bearish
Divi's Laboratories	₹9,623.50	▲ +0.28%	₹2,55,474 Cr	73.32	11.48	16.87%	24.32%	0.41%	Bullish
Torrent Pharmaceuticals	₹4,935.65	▼ −0.89%	₹1,87,730 Cr	72.73	19.22	23.00%	15.29%	0.80%	Bullish
Cipla	₹1,398.30	▲ +1.33%	₹1,12,963 Cr	27.57	3.33	14.47%	13.74%	0.92%	Neutral
Zydus Lifesciences	₹1,180.00	▲ +0.90%	₹1,17,705 Cr	21.19	4.24	17.90%	18.51%	0.09%	Bullish

Rating = the data provider's overall technical view of each peer. Company names link to their own pages.

Shareholding Pattern

Who owns Laurus Labs shares, quarter by quarter (latest on top).

PromoterFIIMFOther

Jun '26

27.5%

28.0%

10.2%

34.4%

Mar '26

Dec '25

Sep '25

Holder	Sep '25	Dec '25	Mar '26	Jun '26	Change
Promoter	27.59%	27.49%	27.49%	27.47%	▼ −0.02 pts
FII	26.17%	26.52%	25.82%	28.00%	▲ +2.18 pts
MF	8.53%	9.49%	11.22%	10.15%	▼ −1.07 pts
Other	37.71%	36.50%	35.47%	34.38%	▼ −1.09 pts

Laurus Labs Key Metrics

Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.

Laurus LabsBenchmarkComfortable → stretched

Valuation Is the price reasonable?

P/E (TTM)Price ÷ yearly earnings per share

74.91

▲ 105% above the sector average of 36.50

P/E, 12-month rangeLow 20.00 · high 190.56

32%

Today's P/E sits 32% of the way from its low to its high

P/BPrice ÷ book value per share

20.72

P/SPrice ÷ sales per share

15.12

P/CFPrice ÷ cash flow per share

69.65

PEGP/E ÷ earnings growth (≈1 is fair)

25.49

Profitability Of every ₹100 of sales, how much is kept?

Gross marginKept after the cost of goods

61.29%

▲ above its 5-yr average of 49.08%

Operating marginKept after running costs

21.28%

▲ above its 5-yr average of 16.89%

Pre-tax marginKept before tax

19.79%

▲ above its 5-yr average of 14.43%

Net marginKept as profit

15.00%

▲ above its 5-yr average of 10.72%

Returns & efficiency How well does it use its money?

Return on equityProfit on shareholders' money

18.19%

▲ above its 5-yr average of 15.19%

Return on assetsProfit on everything it owns

8.97%

▲ above its 5-yr average of 7.51%

Return on investmentProfit on long-term capital

14.34%

▲ above its 5-yr average of 11.95%

Growth Is the business getting bigger?

Revenue — last 12 months

+22.6%

▲ growing

Revenue — 3 yr, a year

+4.1%

▲ growing

Revenue — 5 yr, a year

+7.2%

▲ growing

EPS — last 12 months

+114.5%

▲ growing (off the scale)

EPS — 3 yr, a year

+4.0%

▲ growing

EPS — 5 yr, a year

−2.1%

▼ shrinking

Dividend — 3 yr, a year

+18.6%

▲ growing

Book value — 5 yr, a year

+15.2%

▲ growing

Financial strength Can it pay its bills and debts?

Debt to equityBorrowings for every ₹1 of shareholders' money

0.48×

✓ Low debt

Current ratioShort-term assets for every ₹1 due within a year

1.33×

• Adequate

Quick ratioLike the current ratio, without inventory

0.68×

! Tight

Interest coverOperating profit ÷ interest to pay

10.23×

✓ Strong

Payout ratioShare of profit paid as dividend

12.15%

• Keeps most

Per share What each share stands for

EPS (TTM)

₹20.23

Book value

₹98.17

Cash flow

₹29.19

Dividend

₹2.00

Revenue

₹134.48

The share price is 20.76× the book value behind each share.

Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.

All 109 metrics from the data provider

Valuation

P/E excluding extraordinary items, most recent fiscal year123.68

Current Dividend Yield - Common Stock Primary Issue, LTM0.10

Price to Book - most recent fiscal year20.72

P/E Basic excluding extraordinary items - TTM74.91

P/E including extraordinary items - TTM100.57

P/E excluding extraordinary items low, trailing 12 months20.00

Price to Tangible Book - most fiscal year21.83

Price to sales - most recent fiscal year16.13

Dividend Yield - indicated annual dividend divided by closing price0.10

Price to Cash Flow per share - trailing 12 month69.65

Peg Ratio25.49

Price to Free Cash Flow per Share - most recent fiscal year235.22

P/E Normalized, most recent fiscal year122.96

P/E excluding extraordinary items high, trailing 12 months190.56

P/E excluding extraordinary items, most recent fiscal year quarter100.57

Price to sales - trailing 12 month15.12

Net Debt, LFY24,058.20

Per share

Cash Flow per share - trailing 12 month29.19

Cash Flow per share - most recent fiscal year25.35

EPS including extraordinary items - trailing 12 month20.23

EPS including extraordinary items - most recent fiscal year16.45

EBITD per share - trailing 12 month37.62

Revenue/share - trailing 12 month134.48

EPS excluding extraordinary items - trailing 12 month20.23

EPS Basic excluding extraordinary items - most recent fiscal year16.47

EPS Basic excluding extraordinary items - trailing 12 month20.26

Book value per share - most recent fiscal year98.18

Dividend per share - most recent fiscal year2.00

Revenue/share - most recent fiscal year126.06

EPS Normalized - most recent fiscal year16.54

Book value (tangible) per share - most recent fiscal year93.27

Dividends per share - trailing 12 month2.00

EPS excluding extraordinary items - most recent fiscal year16.45

Cash per share - most recent fiscal year2.09

Margins

Operating margin - trailing 12 month21.28

Gross Margin - 5 year average49.08

Operating margin - 1st historical fiscal year19.16

Operating Margin - 5 year average16.89

Net Profit Margin % - 1st historical fiscal year13.06

Gross Margin - 1st historical fiscal year53.99

Net Profit Margin % - trailing 12 month15.00

Net Profit Margin - 5 year average10.72

Pretax Margin - 5 year average14.43

Pretax margin - 1st historical fiscal year17.35

Pretax margin - trailing 12 month19.79

Free Operating Cash Flow/Revenue, 5 Year Average0.46

Gross Margin - trailing 12 month61.29

Growth

EPS Change %, TTM over TTM114.46

Revenue growth rate, 5 year7.19

EPS growth rate, 5 year−2.09

Revenue Change % - most recent quarter 1 year ago29.10

Growth rate% - dividend, 3 year18.56

Growth rate% - EPS, 3 year3.95

Revenue/share (5 yr growth)7.10

Tangible Book Value, Total Equity, 5 Year CAGR16.54

Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR4.05

Capital Spending growth rate, 5 year9.21

Revenue Change %, TTM over TTM22.62

Growth rate% - Revenue, 3 year4.09

Book value per share growth rate, 5 year15.19

EPS Change % - most recent quarter 1 year ago125.17

Net Profit Margin growth rate, 5 year−8.57

Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR2.85

Total Debt, 5 Year CAGR11.19

Financial strength

Net Interest coverage - most recent fiscal year10.23

Free Cash Flow - most recent fiscal year4,672.20

LT debt/equity - most recent fiscal year0.14

Quick ratio - most recent fiscal year0.68

Payout ratio - trailing 12 month9.87

Current ratio - most recent fiscal year1.33

Current EV/Free Cash Flow, LFY526.34

Total debt/total equity - most recent fiscal year0.48

Net Interest coverage - trailing 12 month9.99

Payout ratio - most recent fiscal year12.15

Returns & efficiency

Return on average equity - 5 year average15.19

Net Income/employee - trailing 12 month15,45,205.00

Revenue/employee - most recent fiscal year1,03,02,280.00

Return on investment - most recent fiscal year14.34

Return on average assets - most recent fiscal year8.97

Receivables turnover - most recent fiscal year3.27

Inventory turnover - most recent fiscal year1.47

Revenue/employee - trailing 12 month1,02,98,400.00

Return on average assets - 5 year average7.51

Net Income/employee - most recent fiscal year13,45,607.00

Asset turnover - most recent fiscal year0.69

Return on average equity - most recent fiscal year18.19

Return on investment - 5 year average11.95

Price & volume

Market Cap1,10,742.40

52 week Low Date26 Sep 2025

Price - 1 Day % Change1.37

Relative (S&P500) price percent change - 13 week43.91

Avg trading volume last 10 days1.89

Price - 13 week price percent change39.87

Price - 52 week price percent change123.50

Avg Trading Volume Last 3 months57.06

Price - 5 Day % Change6.74

Price % Change Month To Date6.21

Relative (S&P500) price percent change - 04 week11.60

52 week High Date23 Sep 2026

Price - 26 week price percent change98.73

PDATE23 Sep 2026

Price - YTD price percent change83.57

Relative (S&P500) price percent change - 52 week145.23

NPRICE2,034.00

Relative (S&P500) price percent change - 26 week99.91

52 week Low823.10

52 week High2,037.20

Beta0.96

Relative (S&P500) price percent change - Year to Date109.07

Dividends & Corporate Events

Payouts to shareholders, splits and bonus issues, and company meetings — newest first.

Dividend per share₹ per share, by fiscal year

₹2.00

Dividend yield0.10%
Payout ratio12.15%
Latest dividend₹1.20 per share · 8 May 2026

Corporate calendar

24 Jul 2026BoardQuarterly Results
2 Jul 2026MeetingAnnual General Meeting
8 May 2026Dividend₹1.20 per share · 60% · Interim dividend
30 Apr 2026BoardAudited Results & Interim Dividend
23 Jan 2026BoardQuarterly Results
31 Oct 2025Dividend₹0.80 per share · 40% · Interim dividend
23 Oct 2025BoardQuarterly Results & Interim Dividend
25 Jul 2025BoardQuarterly Results

Show 14 older events

26 Jun 2025MeetingAnnual General Meeting
9 May 2025Dividend₹0.80 per share · 40% · Interim dividend
24 Apr 2025BoardAudited Results & Interim Dividend
24 Jan 2025BoardQuarterly Results
6 Nov 2024Dividend₹0.40 per share · 20% · Interim dividend
24 Oct 2024BoardQuarterly Results & Interim Dividend
5 Oct 2024MeetingPostal Ballot
11 Jul 2024MeetingAnnual General Meeting
8 May 2024Dividend₹0.40 per share · 20% · Interim dividend
2 Nov 2023Dividend₹0.40 per share · 20% · Interim dividend
14 Jul 2023MeetingAnnual General Meeting
10 May 2023Dividend₹1.20 per share · 60% · Interim dividend
11 Mar 2023MeetingPostal Ballot
3 Nov 2022Dividend₹0.80 per share · 40% · Interim dividend

About Laurus Labs

Biotechnology & Drugs

Laurus Labs Limited is an India-based company. The Company is a pharmaceutical manufacturing organization. It is engaged in developing and manufacturing active pharmaceutical ingredients (APIs) and intermediates. It supplies anti-retroviral APIs and intermediates. It provides contract and custom manufacturing solutions, allowing client organizations to outsource various stages of the manufacturing process. It is also engaged in development and manufacturing of animal-origin-free recombinant proteins, growth factors, and cell-culture media supplements catering to the needs of stem cells and regenerative medicine, vaccines and biological drugs, cultured meat, and cell-culture media manufacturing. It offers precision fermentation as a contract development and manufacturing organization (CDMO) service. Its service is offered to protein companies and bio-manufacturers operating across healthcare, food, nutrition, personal care, and bio-based materials markets.

Key people

Satyanarayana ChavaChief Executive Officer, Executive Director
Venkata Vantaram Ravi KumarChief Financial Officer, Executive Director
V. Uma Maheswer RaoPresident - Chemical R&D
Srinivasa Rao SuryadevaraPresident - Manufacturing and Operations
Thomas VersoskyPresident - FDF, North America
Sita RamaiahExecutive Vice President - Finance

Company facts

NSE symbolLAURUSLABS
BSE code540222
ISININE947Q01028
IndustryBiotechnology & Drugs
IndexNIFTY 500
Market cap₹1,09,991 Cr
Revenue (FY26)₹6,813 Cr
Net profit (FY26)₹889 Cr

In the News

Recent headlines about Laurus Labs — they open on Mint in a new tab.

Chandan Taparia of Motilal Oswal recommends 3 stocks to buy: Laurus Labs, BHEL, HDFC Life; check stop-loss, target price
The Indian stock market is set to open flat on September 18, with mixed global cues. Nifty 50 is staying within a range, while Bank Nifty shows selling pressure after failing to maintain higher levels.
18 Sep 2026 · 3 min read · Mint ↗
Stock market today: Trade guide for Sensex, Nifty 50, crude oil to gold | Seven stocks to buy
Stock market today: The Indian stock market is set to open lower amid mixed global signals, with the Nifty 50 closing below 23,700. Analysts indicate weak momentum, identifying support levels around 23,600 and resistance near 23,800. Meanwhile, oil prices rise due to tensions in the Gulf region.
9 Sep 2026 · 5 min read · Mint ↗
Stock market today: Gift Nifty down | Vaishali Parekh recommends three stocks to buy today
Vaishali Parekh's stock recommendations for today: Prabhudas Lilladher expert picks three stocks for today — Lemon Tree Hotels, HBL Engineering, and Laurus Labs
8 Sep 2026 · 2 min read · Mint ↗
Stock market today: Trade guide for Sensex, Nifty 50, crude oil to gold | Eight stocks to buy
Stock market today: Indian stock market indices Sensex and Nifty 50 are set for a lower open on 8 September amid mixed global cues. Nifty 50 closed below 23,800, signaling bearish momentum, while elevated crude oil prices and geopolitical tensions raise concerns over inflation and market sentiment.
8 Sep 2026 · 5 min read · Mint ↗
Welspun Corp, Piramal Finance, Divis Labs among 12 BSE 500 stocks that jumped to their record highs today; do you own?
Some 17 stocks scaled their 52-week highs in the BSE 500 index, among which 12, including Welspun Corp, Piramal Finance, and Divis Laboratories, jumped to their record highs.
28 Aug 2026 · 2 min read · Mint ↗
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 28 August 2026
The Indian stock market is set to open flat, following weak global trends. Major indices Nifty 50 and Sensex ended lower, with Nifty closing below 24,100. Analyst Chandan Taparia suggests cautious trading within defined ranges and recommends buying Sona BLW, Laurus Labs, and BHEL shares.
28 Aug 2026 · 3 min read · Mint ↗
Stock market today: Gift Nifty hints a positive start; eight day trading stocks to buy on Wednesday, 26 August
The Indian stock market is expected to open higher on 26 August, following positive global cues. The Nifty and Sensex ended the previous session positively, aided by falling oil prices amid diplomatic efforts in the Strait of Hormuz.
26 Aug 2026 · 5 min read · Mint ↗
15 Nifty 500 stocks that doubled investors’ money since last Independence Day: Do you own any?
Despite a challenging year for Indian equities, marked by a 2% dip in the Nifty 50, the broader Nifty 500 index has revealed surprising winners. Discover the 15 stellar stocks that have doubled investor money, amidst geopolitical and economic tides.
15 Aug 2026 · 2 min read · Mint ↗

Stock data comes from the exchange feed via our data provider and may be delayed. It is for information only and is not a recommendation to buy or sell. See all stocks →

Frequently Asked Questions

Laurus Labs (NSE: LAURUSLABS) last traded at ₹2,037.50 on the NSE, up 0.04% (₹0.81) on the day, as of 24 Sep 2026, 8:53 AM. On the BSE it was ₹2,035.70. The day's range was ₹2,020.10 – ₹2,054.55.

Laurus Labs's 52-week high is ₹2,037.45 (23 Sep 2026) and its 52-week low is ₹822.85 (26 Sep 2025). At ₹2,037.50 the share is 0.0% below its high and 147.6% above its low.

Laurus Labs's market capitalisation is ₹1,09,991 Cr (₹1.10L Cr). It is part of the NIFTY 500 index.

Laurus Labs's P/E ratio (trailing 12 months) is 74.91. The sector average is 36.50, so investors pay 105% more for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹20.23.

Laurus Labs shares are up 123.50% over the last year, up 83.57% so far this year, up 98.73% over 6 months, up 39.87% over 3 months. Over the last year the stock did 145.23% better than the market.

In FY26 (year to Mar 2026), Laurus Labs reported revenue of ₹6,813 Cr (up 22.67% on the year before) and a net profit of ₹889 Cr. Earnings per share were ₹16.45.

Yes. Laurus Labs's latest dividend is ₹1.20 per share (60%, interim dividend), with an ex-date of 8 May 2026. The dividend yield is 0.10%. It has paid 8 dividends in the records shown on this page.

Of 12 analysts covering Laurus Labs, 5 are bullish (2 strong buy, 3 buy), 3 say hold and 4 are bearish. The consensus is Hold (average rating 2.83 on a scale where 1 is Strong Buy and 5 is Strong Sell). Analyst views are opinions, not a guarantee.

As of Jun 2026: Promoter 27.47%, FII 28.00%, MF 10.15%, Other 34.38%. Promoter holding fell by 0.02 percentage points from Mar 2026.

Laurus Labs's listed peers in Biotechnology & Drugs include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, Zydus Lifesciences. By market capitalisation it ranks #6 of 6 in this group.

Price returns

Moving averages — price is above 6 of 6

Year by year

Quarter by quarter

Balance sheet — FY26

Cash flow — FY26

Votes

How the votes changed

Valuation Is the price reasonable?

Profitability Of every ₹100 of sales, how much is kept?

Returns & efficiency How well does it use its money?

Growth Is the business getting bigger?

Financial strength Can it pay its bills and debts?

Per share What each share stands for

Valuation

Per share

Margins

Growth

Financial strength

Returns & efficiency

Price & volume

Corporate calendar

Key people

Company facts

Frequently Asked Questions

What is Laurus Labs share price today?

What is the 52-week high and low of Laurus Labs shares?

What is the market capitalisation of Laurus Labs?

What is the P/E ratio of Laurus Labs?

How has Laurus Labs stock performed?

What were Laurus Labs's latest annual results?

Does Laurus Labs pay a dividend?

What do analysts recommend for Laurus Labs shares?

What is the shareholding pattern of Laurus Labs?

Who are Laurus Labs's competitors?